MS8847
Based on 1 Customer Validation
MS8847 is a PROTAC degrader and antiproliferative agent targeting EZH2 (DC50=34.4 nM in EOL-1 MLL-rAML cells). MS8847 recruits the E3 ligase von Hippel-Lindau (VHL) to mediate the degradation of EZH2 via the ubiquitin-proteasome system. MS8847 induces antiproliferative effects in MLL-rearranged acute myeloid leukemia cells and inhibits the growth of triple-negative breast cancer cell lines or 3D triple-negative breast cancer models. MS8847 is applicable to research related to MLL-rearranged acute myeloid leukemia and triple-negative breast cancer.
(Pink: EZH2 ligand (HY-185582); Blue: ligand (HY-125845); Black: linker (HY-W014831)).
For research use only. We do not sell to patients.
- Purity : 99.78%
- CAS No.: 3050872-59-5
- Formula: C70H98N10O8S
- Molecular Weight:1239.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
VHL |
EZH2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BT-549 | IC50 |
1.45 μM
Compound: 8; MS8847
|
Anti-proliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 5 days incubation by CCK-8 assay
Anti-proliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 5 days incubation by CCK-8 assay
|
[PMID: 38295690] |
| EOL1 | IC50 |
0.11 μM
Compound: 8; MS8847
|
Anti-proliferative activity against human EOL1 cells assessed as cell viability measured after 5 days incubation by CCK-8 assay
Anti-proliferative activity against human EOL1 cells assessed as cell viability measured after 5 days incubation by CCK-8 assay
|
[PMID: 38295690] |
| MDA-MB-468 | IC50 |
0.45 μM
Compound: 8; MS8847
|
Anti-proliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 5 days incubation by CCK-8 assay
Anti-proliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 5 days incubation by CCK-8 assay
|
[PMID: 38295690] |
| MV4-11 | IC50 |
0.17 μM
Compound: 8; MS8847
|
Anti-proliferative activity against human MV4-11 cells assessed as cell viability measured after 5 days incubation by CCK-8 assay
Anti-proliferative activity against human MV4-11 cells assessed as cell viability measured after 5 days incubation by CCK-8 assay
|
[PMID: 38295690] |
| RS4-11 | IC50 |
0.41 μM
Compound: 8; MS8847
|
Anti-proliferative activity against human RS4-11 cells assessed as cell viability measured after 5 days incubation by CCK-8 assay
Anti-proliferative activity against human RS4-11 cells assessed as cell viability measured after 5 days incubation by CCK-8 assay
|
[PMID: 38295690] |
In Vitro
MS8847 selectively targets EZH2-dependent cell growth and inhibits the proliferation of triple-negative breast cancer (TNBC) cells, with 5-day IC50 values of 1.45 μM (BT549) and 0.45 μM (MDA-MB-468), respectively. It also inhibits the proliferation of MLL-r AML cell lines, with 5-day IC50 values of 0.11 μM (EOL-1), 0.17 μM (MV4;11) and 0.41 μM (RS4;11), respectively[1].
MS8847 (0.1-1 μM; 24 h) completely degrades EZH2 protein in EOL-1 MLL-r AML cells[1].
MS8847 (1 nM-0.3 μM; 24 h) potently degrades EZH2 in a concentration-dependent manner in EOL-1 MLL-rAML cells, with a DC50 of 34.4 nM, and also degrades EED and SUZ12[1].
MS8847 (2.5-20 μM; 5 d) significantly inhibits cell growth and reduces spheroid size in a 3D in vitro BT549 TNBC model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:EOL-1 (MLL-r AML cell line)
-
Concentration:1-1000 nM; 0.03-0.3 μM
-
Incubation Time:24 h
-
Result:Achieved a half-maximal degradation concentration (DC50) of 34.4 nM for EZH2.
Potently degraded PRC2 core component EED, and degraded SUZ12 to a lesser extent.
Reduced the H3K27me3 mark.
-
Cell Line:EOL-1 (MLL-r AML cell line)
-
Concentration:300 nM
-
Incubation Time:2 h; 4 h; 8 h; 12 h; 24 h; 48 h
-
Result:Initiated EZH2 degradation at 8 h and reached maximum degradation by 24 h.
Reduced the H3K27me3 mark over time.
-
Cell Line:EOL-1 (MLL-r AML cell line)
-
Concentration:0.03-0.3 μM (direct treatment); 0.5 μM (post 2 h pre-incubation with inhibitors/ligands)
-
Incubation Time:24 h (direct treatment); 24 h (post 2 h pre-incubation with inhibitors/ligands)
-
Result:Effectively induced EZH2 degradation at 0.03, 0.1, 0.3 μM.
Rescued EZH2 degradation induction via pre-treatment with MLN4942, EPZ-6438, or VHL-1.
Failed to induce EZH2 degradation with negative controls MS8847N1 and MS8847N2.
-
Cell Line:EOL-1, MV4;11, RS4;11 (MLL-r AML cell lines)
-
Concentration:0.03-0.3 μM
-
Incubation Time:24 h
-
Result:Induced complete EZH2 degradation at 0.1 and 0.3 μM in EOL-1 cells.
Induced near-complete EZH2 degradation at 0.03, 0.1, 0.3 μM in MV4;11 cells.
Induced EZH2 degradation at 0.1 and 0.3 μM in RS4;11 cells.
-
Cell Line:BT549, MDA-MB-468 (TNBC cell lines)
-
Concentration:0.1-3 μM
-
Incubation Time:48 h
-
Result:Induced potent EZH2 degradation in both BT549 and MDA-MB-468 cells following 48 h treatment.
Parmacokinetics
| Species | Dose | Route | Cmax | Plasma Concentration |
|---|---|---|---|---|
| Mice[1] | 50 mg/kg | i.p. | 3.9 μM | >1 μM |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss Albino (male)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; single dose
-
Result:Observed a maximum plasma concentration (Cmax) of 3.9 μM at 4 hours.
Retained over 1 μM in plasma at 9 hours.
Exhibited no obvious clinical signs of toxicity at the tested dose.
Chemical Information
-
CAS No. 3050872-59-5
-
Appearance Solid
-
Molecular Weight 1239.65
-
Formula C70H98N10O8S
-
Color White to off-white
-
SMILES
CC1=CC(C)=C(CNC(C2=C(C)C(N(C3CCOCC3)CC)=CC(C4=CC=C(CN5CCN(CCC(NCCCCCCCCCCC(N[C@@H](C(C)(C)C)C(N6[C@H](C(NCC7=CC=C(C8=C(C)N=CS8)C=C7)=O)C[C@@H](O)C6)=O)=O)=O)CC5)C=C4)=C2)=O)C(N1)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (80.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8067 mL | 4.0334 mL | 8.0668 mL | 20.1670 mL |
| 5 mM | 0.1613 mL | 0.8067 mL | 1.6134 mL | 4.0334 mL | |
| 10 mM | 0.0807 mL | 0.4033 mL | 0.8067 mL | 2.0167 mL | |
| 15 mM | 0.0538 mL | 0.2689 mL | 0.5378 mL | 1.3445 mL | |
| 20 mM | 0.0403 mL | 0.2017 mL | 0.4033 mL | 1.0083 mL | |
| 25 mM | 0.0323 mL | 0.1613 mL | 0.3227 mL | 0.8067 mL | |
| 30 mM | 0.0269 mL | 0.1344 mL | 0.2689 mL | 0.6722 mL | |
| 40 mM | 0.0202 mL | 0.1008 mL | 0.2017 mL | 0.5042 mL | |
| 50 mM | 0.0161 mL | 0.0807 mL | 0.1613 mL | 0.4033 mL | |
| 60 mM | 0.0134 mL | 0.0672 mL | 0.1344 mL | 0.3361 mL | |
| 80 mM | 0.0101 mL | 0.0504 mL | 0.1008 mL | 0.2521 mL |